Adverum Biotechnologies Provides Program Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Adverum Biotechnologies (ADVM) PT Lowered to $4.50 at Chardan Capital Markets
November 2, 2018 9:05 AM EDTChardan Capital Markets analyst Gbola Amusa lowered the price target on Adverum Biotechnologies (NASDAQ: ADVM) to $4.50 (from $8.00) while maintaining a Neutral rating.
... MoreSunTrust Robinson Humphrey Downgrades Adverum Biotechnologies (ADVM) to Hold
November 2, 2018 6:23 AM EDTSunTrust Robinson Humphrey analyst Edward Nash downgraded Adverum Biotechnologies (NASDAQ: ADVM) from Buy to Hold with a price target of $4.00 (from $11.00).
Nash said they were surprised ADVM-043 is being discontinued due to lack of efficacy. Further, he highlights the company's second gene... More
